WuXi Vaccines Signs Twenty Years Manufacturing Agreement with Global Vaccine Leaders for $3B

Shots:

• Wuxi Vaccines to establish new manufacturing facility which includes drug substance manufacturing (DS), drug product manufacturing (DP), manufacture science and technology labs (MS&T) as well as quality control labs (QC)
• The facility will develop and manufacture partner’s vaccine therapy for the global market. The new facility is expected to be operational in 2022
• Additionally, in Nov’2019, Wuxi invests $240M to establish a new vaccine manufacturing facility in Ireland. Wuxi biologics will provide its global partners with a robust and premier-quality supply chain network to develop high-quality vaccines protecting humans globally

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bio Spectrum Asia